ARCHIVES

Faulding, NaPro In Agreement For Marketing Paclitaxel.

This article is from The Cancer Letter archive.

Vol. 27 No. 13 | March 30, 2001

Download PDF Visit The Full Archive

Related Articles

FDA Approves Lilly’s Alimta For Metastatic NSCLC

August 27, 2004

“Triple-Negative” Should Be Split Into Subtypes, Say Researchers

February 22, 2013

Robert Weinburger, Ernst Wynder Win Top Milken Awards

November 2, 1990

Natcher Subcommittee Open Door To justification for Increasing Cancer Program 1982 Appropriation

April 3, 1981

FDA Commissioner Says Swifter Drug Approvals, Enforcement Emphasis Characterize ‘Today’s FDA’

January 31, 1992

Continuing Progress Reported On Breast Cancer Treatment; Mammography Controversy Cooled

November 26, 1976